1. Generics Bulletin
  2. >>Products
  3. >>Biosimilars

Biosimilars: US FDA Developing Guidance For First Interchangeable Exclusivity

First Interchangeable Biosimilar Approved Is Entitled To One Year Of Exclusivity

 
• By Derrick Gingery

The first biosimilar with interchangeability status compared to its reference will be entitled to one year of exclusivity, a largely overlooked advantage in the early days of the US biosimilar market.

Railway tracks with switches and interchanges at a main line in Germany with geometrical structures black and white
First interchangeable exclusivity guidance is one of several the FDA is writing in the interchangeability area • Source: Shutterstock

US Food and Drug Administration officials are moving to set biosimilar interchangeability exclusivity policy as some products seeking the designation may be approaching the approval stage.

The first interchangeable biosimilar approved is entitled to one year of exclusivity per the Biologics Price Competition and Innovation Act...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

Kashiv’s Xolair Biosimilar Nears US And EU Filings As Phase III Data Reports

 
• By Urtė Fultinavičiūtė

Following the filing acceptance in the UK earlier this year, Kashiv and its three commercial musketeers – Alvotech, Advanz Pharma, and Amneal – are getting ready for applications in the US and Europe.

Formycon Signs US-Canada Deal With Valorum Biologics For Eylea Biosimilar

 
• By Urtė Fultinavičiūtė

Formycon continues to expand its partnership network with a fresh deal for its aflibercept biosimilar in the US and Canada. At the same time, the firm has received a high demand for its corporate bonds, leading to early offering closure.

Bio-Thera And SteinCares Add Mega-Blockbuster Dupilumab To Latin America Alliance

 
• By Dean Rudge

Bio-Thera Solutions is back with its third agreement with Costa Rica-based SteinCares for the supply of a biosimilar in Latin America – this time for the Chinese firm’s proposed rival to Sanofi and Regeneron’s Dupixent (dupilumab)

Biocon Agreement Provides Multiple Oncology Biosimilars To Malaysian Cancer NGO

 
• By Dean Rudge

Biocon Biologics will look to combine its “scientific expertise with the National Cancer Society of Malaysia’s strong community outreach and patient support network,” after signing striking up a partnership with the NGO providing for supply of three biosimilars.

More from Products